(TMO) Thermo Fisher Scientific - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8835561023
Reagents, Instruments, Consumables, Software, Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.30% |
| Yield on Cost 5y | 0.38% |
| Yield CAGR 5y | 15.39% |
| Payout Consistency | 42.3% |
| Payout Ratio | 7.7% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 22.3% |
| Value at Risk 5%th | 33.8% |
| Relative Tail Risk | -7.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | -4.53 |
| CAGR/Max DD | 0.06 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.326 |
| Beta | 0.852 |
| Beta Downside | 1.011 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.28% |
| Mean DD | 13.00% |
| Median DD | 10.83% |
Description: TMO Thermo Fisher Scientific December 02, 2025
Thermo Fisher Scientific (NYSE:TMO) delivers a broad portfolio of life-sciences solutions, analytical instruments, specialty diagnostics, and laboratory products across North America, Europe, Asia-Pacific and other international markets. Its four operating segments-Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services-cover everything from reagents and consumables for drug discovery to complete clinical-diagnostic test systems and contract manufacturing for pharma pipelines.
Key recent metrics reinforce the company’s market position: FY 2023 revenue reached $12.6 billion, with an adjusted operating margin of roughly 15 % and a 9 % year-over-year earnings-per-share growth driven by strong demand for COVID-19 testing kits and expanding biopharma outsourcing services. Core sector drivers include rising global R&D spending (projected to exceed $2 trillion by 2027) and an aging population that fuels demand for diagnostic and therapeutic development.
For a deeper quantitative dive, the TMO analysis on ValueRay provides the data and tools needed to evaluate the stock’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (6.57b TTM) > 0 and > 6% of Revenue (6% = 2.62b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -1.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 16.94% (prev 21.67%; Δ -4.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 7.65b > Net Income 6.57b (YES >=105%, WARN >=100%) |
| Net Debt (33.70b) to EBITDA (11.33b) ratio: 2.97 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (378.0m) change vs 12m ago -1.56% (target <= -2.0% for YES) |
| Gross Margin 39.81% (prev 39.79%; Δ 0.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.01% (prev 42.22%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.94 (EBITDA TTM 11.33b / Interest Expense TTM 1.44b) >= 6 (WARN >= 3) |
Altman Z'' 3.89
| (A) 0.07 = (Total Current Assets 22.30b - Total Current Liabilities 14.89b) / Total Assets 103.02b |
| (B) 0.54 = Retained Earnings (Balance) 55.90b / Total Assets 103.02b |
| (C) 0.08 = EBIT TTM 8.54b / Avg Total Assets 101.69b |
| (D) 1.03 = Book Value of Equity 53.55b / Total Liabilities 52.00b |
| Total Rating: 3.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 55.78
| 1. Piotroski 6.50pt |
| 2. FCF Yield 2.47% |
| 3. FCF Margin 13.97% |
| 4. Debt/Equity 0.70 |
| 5. Debt/Ebitda 2.97 |
| 6. ROIC - WACC (= 1.03)% |
| 7. RoE 13.11% |
| 8. Rev. Trend -23.71% |
| 9. EPS Trend -31.63% |
What is the price of TMO shares?
As of December 30, 2025, the stock is trading at USD 580.74 with a total of 347,379 shares traded.
Over the past week, the price has changed by +0.88%, over one month by -1.63%, over three months by +25.78% and over the past year by +12.33%.
Over the past week, the price has changed by +0.88%, over one month by -1.63%, over three months by +25.78% and over the past year by +12.33%.
Is TMO a buy, sell or hold?
Thermo Fisher Scientific has received a consensus analysts rating of 4.39.
Therefore, it is recommended to buy TMO.
- Strong Buy: 18
- Buy: 7
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TMO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 635.8 | 9.5% |
| Analysts Target Price | 635.8 | 9.5% |
| ValueRay Target Price | 585.6 | 0.8% |
TMO Fundamental Data Overview December 23, 2025
Market Cap USD = 213.34b (213.34b USD * 1.0 USD.USD)
P/E Trailing = 32.7846
P/E Forward = 22.8833
P/S = 4.8779
P/B = 4.1816
P/EG = 2.1015
Beta = 0.902
Revenue TTM = 43.74b USD
EBIT TTM = 8.54b USD
EBITDA TTM = 11.33b USD
Long Term Debt = 31.86b USD (from longTermDebt, last quarter)
Short Term Debt = 3.82b USD (from shortTermDebt, last quarter)
Debt = 35.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 33.70b USD (from netDebt column, last quarter)
Enterprise Value = 247.04b USD (213.34b + Debt 35.68b - CCE 1.98b)
Interest Coverage Ratio = 5.94 (Ebit TTM 8.54b / Interest Expense TTM 1.44b)
FCF Yield = 2.47% (FCF TTM 6.11b / Enterprise Value 247.04b)
FCF Margin = 13.97% (FCF TTM 6.11b / Revenue TTM 43.74b)
Net Margin = 15.02% (Net Income TTM 6.57b / Revenue TTM 43.74b)
Gross Margin = 39.81% ((Revenue TTM 43.74b - Cost of Revenue TTM 26.32b) / Revenue TTM)
Gross Margin QoQ = 41.83% (prev 37.29%)
Tobins Q-Ratio = 2.40 (Enterprise Value 247.04b / Total Assets 103.02b)
Interest Expense / Debt = 0.97% (Interest Expense 347.0m / Debt 35.68b)
Taxrate = 11.32% (207.0m / 1.83b)
NOPAT = 7.57b (EBIT 8.54b * (1 - 11.32%))
Current Ratio = 1.50 (Total Current Assets 22.30b / Total Current Liabilities 14.89b)
Debt / Equity = 0.70 (Debt 35.68b / totalStockholderEquity, last quarter 51.02b)
Debt / EBITDA = 2.97 (Net Debt 33.70b / EBITDA 11.33b)
Debt / FCF = 5.51 (Net Debt 33.70b / FCF TTM 6.11b)
Total Stockholder Equity = 50.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.38% (Net Income 6.57b / Total Assets 103.02b)
RoE = 13.11% (Net Income TTM 6.57b / Total Stockholder Equity 50.13b)
RoCE = 10.41% (EBIT 8.54b / Capital Employed (Equity 50.13b + L.T.Debt 31.86b))
RoIC = 8.99% (NOPAT 7.57b / Invested Capital 84.22b)
WACC = 7.96% (E(213.34b)/V(249.02b) * Re(9.15%) + D(35.68b)/V(249.02b) * Rd(0.97%) * (1-Tc(0.11)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF Debug] Terminal Value 74.33% ; FCFE base≈6.78b ; Y1≈6.77b ; Y5≈7.18b
Fair Price DCF = 277.8 (DCF Value 104.37b / Shares Outstanding 375.7m; 5y FCF grow -0.66% → 3.0% )
EPS Correlation: -31.63 | EPS CAGR: -3.20% | SUE: 2.25 | # QB: 1
Revenue Correlation: -23.71 | Revenue CAGR: 1.03% | SUE: 2.45 | # QB: 3
EPS next Quarter (2026-03-31): EPS=5.59 | Chg30d=-0.010 | Revisions Net=+4 | Analysts=17
EPS next Year (2026-12-31): EPS=24.65 | Chg30d=+0.009 | Revisions Net=-3 | Growth EPS=+8.5% | Growth Revenue=+5.1%
P/E Trailing = 32.7846
P/E Forward = 22.8833
P/S = 4.8779
P/B = 4.1816
P/EG = 2.1015
Beta = 0.902
Revenue TTM = 43.74b USD
EBIT TTM = 8.54b USD
EBITDA TTM = 11.33b USD
Long Term Debt = 31.86b USD (from longTermDebt, last quarter)
Short Term Debt = 3.82b USD (from shortTermDebt, last quarter)
Debt = 35.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 33.70b USD (from netDebt column, last quarter)
Enterprise Value = 247.04b USD (213.34b + Debt 35.68b - CCE 1.98b)
Interest Coverage Ratio = 5.94 (Ebit TTM 8.54b / Interest Expense TTM 1.44b)
FCF Yield = 2.47% (FCF TTM 6.11b / Enterprise Value 247.04b)
FCF Margin = 13.97% (FCF TTM 6.11b / Revenue TTM 43.74b)
Net Margin = 15.02% (Net Income TTM 6.57b / Revenue TTM 43.74b)
Gross Margin = 39.81% ((Revenue TTM 43.74b - Cost of Revenue TTM 26.32b) / Revenue TTM)
Gross Margin QoQ = 41.83% (prev 37.29%)
Tobins Q-Ratio = 2.40 (Enterprise Value 247.04b / Total Assets 103.02b)
Interest Expense / Debt = 0.97% (Interest Expense 347.0m / Debt 35.68b)
Taxrate = 11.32% (207.0m / 1.83b)
NOPAT = 7.57b (EBIT 8.54b * (1 - 11.32%))
Current Ratio = 1.50 (Total Current Assets 22.30b / Total Current Liabilities 14.89b)
Debt / Equity = 0.70 (Debt 35.68b / totalStockholderEquity, last quarter 51.02b)
Debt / EBITDA = 2.97 (Net Debt 33.70b / EBITDA 11.33b)
Debt / FCF = 5.51 (Net Debt 33.70b / FCF TTM 6.11b)
Total Stockholder Equity = 50.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.38% (Net Income 6.57b / Total Assets 103.02b)
RoE = 13.11% (Net Income TTM 6.57b / Total Stockholder Equity 50.13b)
RoCE = 10.41% (EBIT 8.54b / Capital Employed (Equity 50.13b + L.T.Debt 31.86b))
RoIC = 8.99% (NOPAT 7.57b / Invested Capital 84.22b)
WACC = 7.96% (E(213.34b)/V(249.02b) * Re(9.15%) + D(35.68b)/V(249.02b) * Rd(0.97%) * (1-Tc(0.11)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF Debug] Terminal Value 74.33% ; FCFE base≈6.78b ; Y1≈6.77b ; Y5≈7.18b
Fair Price DCF = 277.8 (DCF Value 104.37b / Shares Outstanding 375.7m; 5y FCF grow -0.66% → 3.0% )
EPS Correlation: -31.63 | EPS CAGR: -3.20% | SUE: 2.25 | # QB: 1
Revenue Correlation: -23.71 | Revenue CAGR: 1.03% | SUE: 2.45 | # QB: 3
EPS next Quarter (2026-03-31): EPS=5.59 | Chg30d=-0.010 | Revisions Net=+4 | Analysts=17
EPS next Year (2026-12-31): EPS=24.65 | Chg30d=+0.009 | Revisions Net=-3 | Growth EPS=+8.5% | Growth Revenue=+5.1%
Additional Sources for TMO Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle